16.05.2018
Medios AG DE000A1MMCC8
DGAP-News: Medios AG enjoys a successful start to the 2018 financial year
DGAP-News: Medios AG / Key word(s): Quarter Results
Medios AG enjoys a successful start to the 2018 financial year
16.05.2018 / 12:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Corporate News
Medios AG enjoys a successful start to the 2018 financial year
* Significant increase in sales and earnings in the first quarter
* Management Board confirms forecast for the full year
Berlin, May 16, 2018 - Medios AG ("Medios"), one of the leading Specialty
Pharma companies in Germany, has enjoyed a successful start to the 2018
financial year and confirms the forecast for the full year after a
significant increase in sales and earnings in the first quarter. In the
period from January to March, Group sales rose by 32 per cent to 68.6
million euros (IFRS; prior year EUR 51.8 million) compared to the same
quarter last year. Without taking into account the 2017 stock option program
(SOP) and one-off expenses of approximately 0.3 million euros within the
context of the proposed acquisition and integration of the operating units
of BerlinApotheke Schneider & Oleski oHG, Group earnings before taxes (EBT)
climbed by 20 per cent to 2.4 million euros (IFRS; prior year EUR 2.0
million). After one-off expenses, the EBT increased by 5 per cent to 2.1
million euros without taking the SOP into account.
Manfred Schneider, CEO of Medios AG: "With the positive business development
in the first quarter and continuing high demand for individualised medicine,
we remain optimistic about achieving our targets for the full year and
continuing the dynamic growth path as planned."
The Management Board is confirming its forecast, which assumes that the
acquired operating units will be integrated and make a significant
contribution to Group sales and EBT from June 2018. For the 2018 financial
year, the Management Board therefore continues to expect Group sales of
around 320 million euros and an EBT, without taking into account the SOP, of
approximately 11 million euros. This represents a considerable growth of 26
per cent and 37 per cent respectively compared to 2017 financial figures
totalling 253 million euros and 8.0 million euros respectively.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As
wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of
patient-specific medications, Medios covers substantial elements of the
supply chain in this field and follows the highest international quality
standards. Specialty Pharma drugs are, in particular, individualised
infusions for patients with rare or chronic diseases like cancer, HIV and
hepatitis. It is Medios' aim to provide integrated solutions along the value
chain to partners and clients, thereby ensuring an optimal pharmaceutical
care for patients.
Medios AG is Germany's first listed Specialty Pharma company. The share
(WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the
Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock
Exchange.
Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Telephone: +49 40 60918618
Fax: +49 40 60918660
E-mail: [email protected]
www.kirchhoff.de
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the
forward-looking statements contained in this notification.
---------------------------------------------------------------------------
16.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP News Service
---------------------------------------------------------------------------
686105 16.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1